Clinical trial · Interventional
A Prospective Clinical Study for Evaluation of Safe Resection Margin in Breast Conserving Surgery in Breast Cancer
A Prospective Clinical Study for Evaluation of Safe Resection Margin in Breast Conserving Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) has been used for breast cancer surgery such as sentinel lymph node (SLN) mapping and breast cancer localization. In this study, our hypothesis are as following: 1. As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome. 2. indocyanine green (ICG) permitted accurate preoperative and intraoperative detection of the SLNs as well as nonpalpable benign brest lesion in patients with breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| indocyanine green | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- indocyanine green
- description
- As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome. Intervention: Drug: indocyanine green
- interventionNames
- Drug: indocyanine green
Primary outcomes (1)
- measure
- detection rate
- timeFrame
- one day
- description
- after complete resection with intraoperative ultrasound confirmed the lesion
Secondary outcomes (1)
- measure
- determine the pathological stability
- timeFrame
- one day
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * nonpalpable breast tumor \< 5cm in patients with breast cancer. * consented patients with more than 18 years * Eastern Cooperative Oncology Group Performance status 0 or 1 * patients who need breast biopsy as treatment for breast cancer. Exclusion Criteria: * nonpalpable breast tumor ≥ 5cm in patients with breast cancer. * inflammatory cancer of breast or patients who need MRM * pregnancy * history of severe allergy to ICG(Indocyanine Green) * iode hypersensitiveness
References
Publications (0)
Data not yet available